Compare Amylx Pharmaceuticals Inc (AMLX) vs Freeport-McMoRan Inc (FCX) Price & Performance

AMLX trades at $23.35, down 1.18% on the day, with strong analyst support (90.9% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum with moving averages supporting upward movement, though RSI levels indicate potential overbought conditions. Recent Q2 2026 earnings missed expectations with a loss of $0.39 per share, but the company maintains significant cash reserves through 2028 and anticipates key Phase 3 trial results for avexitide in late August/September 2026.

The investment case hinges on successful clinical trial outcomes and future revenue generation, with current negative profitability metrics offset by strong institutional backing and promising pipeline catalysts. Key risks include clinical trial failures, ongoing financial losses, and competitive pressures in the biotech sector.

FCX trades at $66.83, down 2.98% on the day, but maintains a bullish technical trend with strong analyst support. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $0.72 EPS. Revenue remains stable around $25.9B, while net income margin improved to 11.38% in 2026. Recent news highlights operational challenges like lower copper volumes but also growth initiatives at Grasberg and Bagdad.

The outlook is positive with a consensus price target of $73.85, implying ~10% upside. Key opportunities include exposure to high copper prices and expansion projects, while risks involve production volatility, cost pressures, and reliance on commodity cycles. The stock's valuation appears elevated with a P/E of 33.93, requiring sustained earnings growth to justify further gains.